Table 1 Comparison of diagnostic performance across different techniques.

From: Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia

Type of alteration

Technique

Detection rate (n/N)

Detection rate (%)

Clinically relevant (n)

Non clinically relevant (n)

Clinically relevant (%)*

p-value

Chr Gains/Losses

Standard-of-care

21/60

35

14

7

66.7

dMLPA

31/60

51.7

19

12

61.3

OGM

31/60

51.7

19

12

61.3

Standard-of-care vs. dMLPA

21/60 vs. 31/60

35 vs. 51.7

14 vs. 19

7 vs. 12

66.7 vs. 61.3

0.0973

Standard-of-care vs. OGM

21/60 vs. 31/60

35 vs. 51.7

14 vs. 19

7 vs. 12

66.7 vs. 61.3

0.0973

dMLPA vs. OGM

31/60 vs. 31/60

51.7 vs 51.7

19 vs. 19

12 vs. 12

61.3 vs. 61.3

1

CNA-UKALL

MLPA

38/60

63.3

38

0

100

dMLPA

38/60

63.3

38

0

100

OGM

36/60

60

36

0

100

MLPA vs. dMLPA

38/60 vs. 38/60

63.3 vs. 63.3

38 vs. 38

0 vs. 0

100 vs. 100

1

MLPA vs. OGM

38/60 vs. 36/60

63.3 vs. 60

38 vs. 36

0 vs. 0

100 vs. 100

0.8510

dMLPA vs. OGM

38/60 vs. 36/60

63.3 vs. 60

38 vs. 36

0 vs. 0

100 vs. 100

0.8510

CNAs

dMLPA

37/60

61.7

2

35

5.4

OGM

38/60

63.3

2

36

5.3

dMLPA vs. OGM

37/60 vs. 38/60

61.7 vs. 63.3

2 vs. 2

35 vs. 36

5.4 vs. 5.3

0.9999

Fusions#

Standard-of-care

18/60

30

13

5

72.2

OGM

34/60

56.7

26

8

76.5

t-NGS

18/60

30

18

0

100

RNAseq

16/20

80

13

3

81.3

Standard-of-care vs. OGM

18/60 vs. 34/60

30 vs. 56.7

13 vs. 26

5 vs. 8

72.2 vs. 76.5

0.0057

Standard-of-care vs. t-NGS

18/60 vs. 18/60

30 vs. 30

13 vs. 13

5 vs. 0

72.2 vs. 100

1

Standard-of-care vs. RNAseq

18/60 vs. 16/20

30 vs. 80

13 vs. 13

5 vs. 3

72.2 vs. 81.3

<0.0001

OGM vs. t-NGS

34/60 vs. 18/60

56.7 vs. 30

26 vs. 18

8 vs. 0

76.5 vs. 100

0.0057

OGM vs. RNAseq

34/60 vs. 16/20

56.7 vs 80

26 vs. 13

8 vs. 3

76.5 vs. 81.3

0.0107

t-NGS vs. RNAseq

18/60 vs. 16/20

30 vs. 80

18 vs. 13

0 vs. 3

100 vs. 81.3

<0.0001

SNV/Indels

t-NGS

52/60

86.7

0

52

0

1

  1. *All alterations included in this analysis were confirmed as true positives. #RNAseq analysis was limited to the 20 cases for which this study was available.